Diseases, Conditions, Syndromes

Adherence to prophylaxis for EGFRi-linked rash beneficial

(HealthDay)—Increasing adherence to evidence-based prophylaxis protocols for epidermal growth factor receptor inhibitor (EGFRi)-associated rash can reduce interventions and toxicity-associated chemotherapy interruptions, ...

page 1 from 6

Cetuximab

Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer.

This text uses material from Wikipedia, licensed under CC BY-SA